High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases
Clinical trial NCT06319950 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06319950
- Sponsor
- Taizhou Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-04-01
- Primary completion
- 2026-12-30
- Enrollment
- 255
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.